Cockrill brings a wealth of knowledge, energy and humility to the growing commercial team
MADISON, WI – May 22, 2025 – EnsoData™, an innovator in AI solutions in sleep medicine, adds Bobby Cockrill, MBA, as Chief Commercial Officer, (CCO). Cockrill will oversee strategy and execution of sales and marketing functions and continue accelerating EnsoSleep PPG™, EnsoSleep™, RPM, and EnsoTherapy™ adoption across North America.
Cockrill comes from Bardy Diagnostics (BDx), where he elevated a lean sales team into a force of sixty+, leading to 100X revenue growth over his eight years. BDx provides patch-based cardiac monitoring solutions that streamline patient workflows and optimize healthcare outcomes, much like the EnsoData suite of solutions.
“Bobby’s extensive experience in cardiac monitoring positions him very well to scale EnsoData’s analogous offerings in sleep. We anticipate significant expansion of the commercial team under Bobby’s leadership and are excited for this next chapter of growth,” stated Dr. Justin Mortara, Ph.D., CEO and President, EnsoData.
“I am excited to join EnsoData and help scale an organization with such a solid foundation of proven AI solutions,” stated Bobby Cockrill, MBA, CCO, EnsoData. “We’re now entering a high-growth phase, and I’m especially energized to expand our reach and grow a world-class team of healthcare sales executives to drive the next chapter.”
—
About EnsoData: EnsoData is a healthcare technology company that uses artificial intelligence (AI) and machine learning (ML) technology to connect sleep disorder diagnosis to therapy, simplifying and accelerating the sleep care pathway for both physicians and patients.
